Skip to main content

ULTRALIFE CORP

For the period ended Jun 30, 2026. Filed Aug 7, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 7, 2026

ULBI$15.66+0.2%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Item 1. Consolidated Financial Statements (unaudited)

Consolidated Balance Sheets as of June 30, 2026 and December 31, 20251
Consolidated Statements of Income and Comprehensive Income for the Three and Six-Month Periods Ended June 30, 2026 and June 30, 20252
Consolidated Statements of Cash Flows for the Six-Month Periods Ended June 30, 2026 and June 30, 20253
Consolidated Statements of Changes in Stockholders’ Equity for the Three and Six-Month Periods Ended June 30, 2026 and June 30, 20254
Notes to Consolidated Financial Statements (unaudited)5
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations19
Item 4.Controls and Procedures28
PART II.OTHER INFORMATION
Item 6.Exhibits30
Signatures31

PART I. FINANCIAL INFORMATION

ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (In Thousands except share amounts) (Unaudited)

June 30, 2026December 31, 2025
ASSETS
Current assets:
Cash$6,663$9,345
Trade accounts receivable, net of allowance for expected credit losses of $462 and $457, respectively34,77033,948
Inventories, net58,74554,008
Prepaid expenses and other current assets6,9808,500
Total current assets107,158105,801
Property, plant and equipment, net39,51440,397
Goodwill45,36945,376
Other intangible assets, net10,38610,933
Deferred income taxes, net10,33510,494
Other noncurrent assets3,3953,911
Total assets$216,157$216,912
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$22,601$17,423
Current portion of long-term debt1,7504,125
Accrued compensation and related benefits2,9302,754
Accrued expenses and other current liabilities10,07413,031
Total current liabilities37,35537,333
Long-term debt, net42,85445,526
Deferred income taxes9341,000
Other noncurrent liabilities2,4132,919
Total liabilities83,55686,778
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock – par value $.10 per share; authorized 1,000,000 shares; none issued--
Common stock – par value $.10 per share; authorized 40,000,000 shares; issued – 21,099,383 shares at June 30, 2026 and 21,092,617 shares at December 31, 2025; outstanding – 16,663,269 shares at June 30, 2026 and 16,656,503 shares at December 31, 20252,1102,109
Capital in excess of par value192,983192,859
Accumulated deficit(38,248)(40,340)
Accumulated other comprehensive loss(2,846)(3,141)
Treasury stock - at cost; 4,436,114 shares at June 30, 2026 and 4,436,114 shares at December 31, 2025(21,492)(21,492)
Total Ultralife Corporation equity132,507129,995
Non-controlling interest94139
Total stockholders’ equity132,601130,134
Total liabilities and stockholders’ equity$216,157$216,912

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

(In Thousands except per share amounts)

(Unaudited)

Three-month period endedSix-month period ended
June 30, 2026June 30, 2025June 30, 2026June 30, 2025
Revenues$47,943$48,561$95,388$99,307
Cost of products sold34,07736,96071,41274,961
Gross profit13,86611,60123,97624,346
Operating expenses:
Research and development3,2252,3186,1864,722
Selling, general and administrative7,2047,02714,56813,969
Total operating expenses10,4299,34520,75418,691
Operating income3,4372,2563,2225,655
Other expense (income):
Interest and financing expense8399921,7072,024
Miscellaneous (income) expense(388)151(808)72
Total other expense4511,1438992,096
Income before income taxes2,9861,1132,3233,559
Income tax provision468243276810
Net income2,5188702,0472,749
Net (loss) income attributable to non-controlling interest(25)(9)(45)5
Net income attributable to Ultralife Corporation2,5438792,0922,744
Other comprehensive income:
Foreign currency translation adjustments2128752951,186
Comprehensive income attributable to Ultralife Corporation$2,755$1,754$2,387$3,930
Net income per share attributable to Ultralife common stockholders – basic$.15$.05$.13$.17
Net income per share attributable to Ultralife common stockholders – diluted$.15$.05$.13$.17
Weighted average shares outstanding – basic16,65916,63516,65816,634
Potential common shares55214537
Weighted average shares outstanding - diluted16,71416,65616,70316,671

ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Dollars in Thousands) (Unaudited)

Six-month period ended
June 30, 2026June 30, 2025
OPERATING ACTIVITIES:
Net income$2,047$2,749
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation2,1101,958
Amortization of intangible assets535815
Amortization of financing fees132133
Stock-based compensation89462
Deferred income taxes93609
Changes in operating assets and liabilities:
Accounts receivable(839)(2,702)
Inventories(4,732)1,102
Prepaid expenses and other assets2,1244,577
Accounts payable and other liabilities1,885(400)
Net cash provided by operating activities3,4449,303
INVESTING ACTIVITIES:
Purchases of property, plant and equipment(1,223)(1,995)
Net cash used in investing activities(1,223)(1,995)
FINANCING ACTIVITIES:
Payments on credit facilities(5,125)(3,375)
Debt issuance costs-(24)
Proceeds from exercise of stock options3661
Net cash used in financing activities(5,089)(3,338)
Effect of exchange rate changes on cash186117
(DECREASE) INCREASE IN CASH(2,682)4,087
Cash, Beginning of period9,3456,854
Cash, End of period$6,663$10,941

The accompanying notes are an integral part of these consolidated financial statements.

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(In thousands except share amounts) (Unaudited)

Capital · Accumulated
Common Stock · in Excess · Other · Non-
Number of · of Par · Comprehensive · Accumulated · Treasury · Controlling
SharesAmountValueIncome (Loss)DeficitStockInterestTotal
Balance – December 31, 202421,069,079$2,107$191,828$(4,006)$(34,442)$(21,492)$192$134,187
Net income2,74452,749
Stock option exercises9,36716061
Stock-based compensation – stock options378378
Stock-based compensation - restricted stock8484
Foreign currency translation adjustments1,1861,186
Balance – June 30, 202521,078,446$2,108$192,350$(2,820)$(31,698)$(21,492)$197$138,645
Balance – December 31, 202521,092,617$2,109$192,859$(3,141)$(40,340)$(21,492)$139$130,134
Net income (loss)2,092(45)2,047
Stock option exercises6,76613536
Stock-based compensation – stock options155155
Stock-based compensation - restricted stock(66)(66)
Foreign currency translation adjustments295295
Balance – June 30, 202621,099,383$2,110$192,983$(2,846)$(38,248)$(21,492)$94$132,601
Balance – March 31, 202521,069,079$2,107$192,055$(3,695)$(32,577)$(21,492)$206$136,604
Net income (loss)879(9)870
Stock option exercises9,36716061
Stock-based compensation – stock options190190
Stock-based compensation - restricted stock4545
Foreign currency translation adjustments875875
Balance – June 30, 202521,078,446$2,108$192,350$(2,820)$(31,698)$(21,492)$197$138,645
Balance – March 31, 202621,092,617$2,109$192,858$(3,058)$(40,791)$(21,492)$119$129,745
Net income (loss)2,543(25)2,518
Stock option exercises6,76613536
Stock-based compensation – stock options7777
Stock-based compensation - restricted stock1313
Foreign currency translation adjustments212212
Balance – June 30, 202621,099,383$2,110$192,983$(2,846)$(38,248)$(21,492)$94$132,601

ULTRALIFE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(In thousands except share and per share amounts)

(Unaudited)

1.BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements of Ultralife Corporation and its subsidiaries (the “Company” or “Ultralife”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Rule 8-03 of Regulation S-X. Accordingly, they do not include all the information and notes for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals and adjustments) considered necessary for a fair presentation of the consolidated financial statements have been included. Results for interim periods should not be considered indicative of results to be expected for a full year. Reference should be made to the consolidated financial statements and related notes thereto contained in our Form 10-K for the year ended December 31, 2025.

The December 31, 2025 consolidated balance sheet information referenced herein was derived from audited financial statements but does not include all disclosures required by GAAP.

Certain items previously reported in specific financial statement captions have been reclassified to conform to the current presentation.

Recent Business Developments

In connection with the importation of certain raw materials and components used in the manufacture of its products, the Company previously paid tariffs imposed pursuant to the International Emergency Economic Powers Act ("IEEPA"). Such tariff costs were included in inventory and recognized in cost of products sold as the related inventory was sold.

During the second quarter of 2026, the Company received cash refunds of previously paid IEEPA tariffs following legal developments related to the validity of certain IEEPA tariffs and the implementation of refund procedures by U.S. Customs and Border Protection. The Company accounts for IEEPA tariff refunds as gain contingencies and recognizes such amounts only when the related contingencies have been resolved and the amounts are realized or realizable. Accordingly, during the three- and six-month periods ended June 30, 2026, the Company recognized a net refund of $1,102 as a reduction of cost of products sold, representing the recovery of tariff costs previously recognized in earnings. The tariff costs related to the refund recognized as a reduction of cost of products sold were not charged to customers and therefore not payable to customers. Additional refunds received related to tariff costs capitalized in inventory on hand at June 30, 2026 were recorded as a reduction of inventory and will be recognized in cost of products sold as the related inventory is sold in future periods. The refund was received in cash during the quarter.

The Company continues to evaluate potential claims for additional IEEPA tariff refunds. Additional recoveries remain subject to governmental review, claim validation, administrative processing and ongoing legal proceedings. Accordingly, as of June 30, 2026, the Company had not recorded a receivable or recognized any amounts related to potential future IEEPA tariff recoveries as realization of such amounts is not considered sufficiently probable at this time.

Recent Accounting Guidance Not Yet Adopted

In November 2024, the FASB issued ASU 2024-03 “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses” which requires public entities to disclose specified information about certain costs and expenses. ASU 2024-03 is effective for the Company’s annual reporting period beginning January 1, 2027, and interim reporting periods beginning January 1, 2028, with early adoption permitted. The Company is currently evaluating the impact that ASU 2024-03 will have on its consolidated financial statements.

2.DEBT

On October 31, 2024, Ultralife, SWE, CLB, Excell USA, and Electrochem, as borrowers, and certain other subsidiaries of the Company, entered into a new Credit and Security Agreement with KeyBank National Association (“KeyBank” or the “Bank”), as lender and administrative agent (the “New Credit Agreement”). The proceeds of the loans under the New Credit Agreement were used, in part, to repay outstanding indebtedness under the Company’s then existing Credit and Security Agreement with KeyBank (the “Amended Credit Agreement”).

The New Credit Agreement, among other things, provides in its term loan provisions for a 5-year, $55 million senior secured term loan (the “Term Loan” or “Term Loan Facility”). The Term Loan is subject to repayment in quarterly installments commencing March 31, 2025, in amounts as set forth in the New Credit Agreement. Interest is payable on the unpaid principal outstanding under the Term Loan. All amounts of unpaid principal and accrued and unpaid interest remaining due under the Term Loan are scheduled to be paid in full October 31, 2029.

Upon closing of the acquisition of all issued and outstanding shares of Electrochem on October 31, 2024, the Company borrowed the full amount of the Term Loan Facility.

As of June 30, 2026, the Company had $45,125 outstanding principal on the Term Loan, $1,750 of which is included in current portion of long-term debt on the consolidated balance sheets, andno amounts outstanding on the Revolving Credit Facility. As of June 30, 2026, unamortized debt issuance costs associated with the Term Loan of $521 are classified on the consolidated balance sheets as a reduction of long-term debt, and unamortized debt issuance costs associated with the Revolving Credit Facility of $360 are classified on the consolidated balance sheets as other noncurrent assets. Debt issuance costs include lender fees and certain costs paid to third parties, including legal and accountant fees, and are amortized to interest expense over the term of the New Credit Agreement.

The New Credit Agreement also provides under its revolving credit provisions for revolving loans, letters of credit, and swing loans (“Revolving Credit Facility”). Upon the effectiveness of the New Credit Agreement, any amounts outstanding under letters of credit issued pursuant to the Amended Credit Agreement became issued under the New Credit Agreement. The availability under the Revolving Credit Facility is subject to certain borrowing base limits based on trade receivables and inventories. All unpaid principal and accrued and unpaid interest with respect to the Revolving Credit Facility is due and payable in full on October 31, 2029.

The Company may voluntarily prepay principal amounts outstanding under the New Credit Agreement at any time subject to certain advance notifications and other restrictions.

In addition to the customary affirmative and negative covenants, the Company must maintain a consolidated fixed charge coverage ratio, as defined in the New Credit Agreement, of equal to or greater than 1.15 to 1.00 for the fiscal quarter ending March 31, 2025, and for each fiscal quarter thereafter, as calculated for the four (4) consecutive fiscal quarters ending on such date, and a consolidated senior leverage ratio, as defined in the New Credit Agreement, not to exceed (i)3.50 to 1.00 for the fiscal quarters ending March 31, 2025 through December 31, 2025, (ii)3.25 to 1.00 for the fiscal quarters ending March 31, 2026 through December 31, 2026, (iii)3.00 to 1.00 for the fiscal quarter ending March 31, 2027 and on the last day of each fiscal quarter thereafter, for the remaining term of the New Credit Agreement. The Company was in full compliance with its covenants under the New Credit Agreement as of June 30, 2026.

Borrowings under the New Credit Agreement are secured by substantially all the assets of the Company and certain of its present and future subsidiaries who are or become parties to, or guarantors under the New Credit Agreement.

Interest will accrue on outstanding indebtedness under the Term Loan Facility and Revolving Credit Facilities at a variable rate of interest based on designated interest rate benchmarks plus a varying margin determined by reference to the consolidated senior leverage ratio in effect from time to time. Our borrowing rate was 6.11% as of June 30, 2026.

The Company must pay a fee of twenty, twenty-five or thirty basis points (depending on the consolidated senior leverage ratio in effect from time to time) based on the average daily unused availability under the Revolving Credit Facility.

The Company must make payments to the extent borrowings exceed the maximum amount then permitted to be borrowed and from the proceeds of certain transactions. Upon the occurrence of an event of default, the outstanding obligations may be accelerated, and the Bank will have other customary remedies including resort to the security interest the Company provided to the Bank.

Future minimum principal repayment obligations on our New Credit Agreement as of June 30, 2026 are as follows:

2026 · $ · -
20274,500
20285,500
202935,125
Total$45,125
3.EARNINGS PER SHARE

Basic earnings (loss) per share (“EPS”) is computed by dividing net income (loss) attributable to Ultralife by the weighted average shares outstanding during the period. Diluted EPS includes the dilutive effect of securities when the average market price exceeds the exercise price of the securities, if any, and is calculated using the treasury stock method.

For the three-month period ended June 30, 2026, there were 295,455 outstanding stock options and 19,543 unvested restricted stock awards included in the calculation of diluted weighted average shares outstanding, as such securities were dilutive, resulting in 55,268 potential common shares included in the calculation of diluted EPS. For the comparable three-month period ended June 30, 2025, there were 214,971 outstanding stock options and 35,486 unvested restricted stock awards included in the calculation of diluted weighted average shares outstanding, as such securities were dilutive, resulting in 21,856 potential common shares included in the calculation of diluted EPS.

There were 649,990 outstanding stock options for the three-month period ended June 30, 2026, and 783,093 outstanding stock options for the comparable three-month period ended June 30, 2025, that were not included in the calculation of diluted weighted average shares outstanding as the effect would be anti-dilutive.

For the six-month period ended June 30, 2026, there were 203,705 outstanding stock options and 19,543 unvested restricted stock awards included in the calculation of diluted weighted average shares outstanding, resulting in 44,992 potential common shares included in the calculation of diluted EPS. For the comparable six-month period ended June 30, 2025, there were 214,971 outstanding stock options and 35,486 unvested restricted stock awards included in the calculation of diluted weighted average shares outstanding, resulting in 37,237 potential common shares included in the calculation of diluted EPS.

There were 741,740 and 783,093 outstanding stock options for the six-month periods ended June 30, 2026 and 2025, respectively, not included in the calculation of diluted weighted average shares outstanding as the effect would be anti-dilutive.

4.SUPPLEMENTAL BALANCE SHEET INFORMATION

Fair Value Measurements and Disclosures

The fair value of financial instruments approximated their carrying values at June 30, 2026, and December 31, 2025. The fair value of cash, accounts receivable, accounts payable, accrued liabilities, and the current portion of long-term debt approximates carrying value due to the short-term nature of these instruments. The carrying value of long-term debt approximates fair value, as the variable interest rates approximate current market rates.

Inventories, Net

Inventories are stated at the lower of cost or net realizable value, net of obsolescence reserves, with cost determined under the first-in, first-out (FIFO) method. The composition of inventories, net was:

June 30,December 31,
20262025
Raw materials$46,516$42,150
Work in process6,0104,045
Finished goods6,2197,813
Total$58,745$54,008

Property, Plant and Equipment, Net

Major classes of property, plant and equipment consisted of the following:

June 30,December 31,
20262025
Land$4,693$4,693
Buildings and leasehold improvements30,87830,179
Machinery and equipment65,38363,556
Furniture and fixtures3,2403,195
Computer hardware and software9,4138,164
Construction in process7623,129
114,369112,916
Less: Accumulated depreciation(74,855)(72,519)
Property, plant and equipment, net$39,514$40,397

Depreciation expense for property, plant and equipment was as follows:

Three-month period endedSix-month period ended
June 30,June 30,June 30,June 30,
2026202520262025
Depreciation expense$1,056$1,008$2,110$1,958

Goodwill

The following table summarizes the goodwill activity by segment for the six-month period ended June 30, 2026:

Battery & Energy · Communications
ProductsSystemsTotal
Balance – December 31, 2025$33,883$11,493$45,376
Effect of foreign currency translation(7)-(7)
Balance – June 30, 2026$33,876$11,493$45,369

Other Intangible Assets, Net

The composition of other intangible assets was:

Accumulated
CostAmortizationNet
Customer relationships$18,291$8,809$9,482
Patents and technology5,7465,637109
Other1,500705795
Total other intangible assets$25,537$15,151$10,386
Accumulated
CostAmortizationNet
Customer relationships$18,333$8,360$9,973
Patents and technology5,7625,635127
Other1,500667833
Total other intangible assets$25,595$14,662$10,933

The change in the cost of total intangible assets from December 31, 2025, to June 30, 2026, is the effect of foreign currency translations.

Amortization expense for other intangible assets was as follows:

Three-month period endedSix-month period ended
June 30,June 30,June 30,June 30,
2026202520262025
Amortization included in:
Selling, general and administrative$263$378$525$754
Research and development5321061
Total amortization expense$268$410$535$815
5.STOCK-BASED COMPENSATION

We recorded non-cash stock compensation expense in each period as follows:

Three-month period endedSix-month period ended
June 30,June 30,June 30,June 30,
2026202520262025
Stock options$77$190$155$378
Restricted stock1345(66)84
Total$90$235$89$462

We have stock options outstanding from various stock-based employee compensation plans for which we record compensation cost relating to share-based payment transactions in our financial statements. As of June 30, 2026, there was $232 of total unrecognized compensation cost related to outstanding stock options, which is expected to be recognized over a weighted average period of 0.8 years.

The following table summarizes stock option activity for the six-month period ended June 30, 2026:

Number of SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (years)Aggregate Intrinsic Value
Outstanding at January 1, 2026967,351$6.95
Granted5,000$5.92
Exercised(6,766)$5.27
Forfeited or expired(20,140)$7.19
Outstanding at June 30, 2026945,445$6.963.30$199
Vested and expected to vest at June 30, 2026892,666$6.923.19$198
Exercisable at June 30, 2026726,427$6.782.73$197

Cash received from stock option exercises under our stock-based compensation plans for the three-month periods ended June 30, 2026, and June 30, 2025, was $36 and $61, respectively. Cash received from stock option exercises under our stock-based compensation plans for the six-month periods ended June 30, 2026, and June 30, 2025, was $36 and $61, respectively.

Restricted stock awards vest in equal annual installments over three (3) years. Unrecognized compensation cost related to unvested restricted shares at June 30, 2026, and 2025, respectively, was $59 and $171.

6.INCOME TAXES

Our effective tax rate for the six-month periods ended June 30, 2026, and 2025 was 11.9% and 22.8%, respectively. The period-over-period change was primarily attributable to the geographic mix of our operating results and other income recognized on nontaxable refundable tax credits under the 45X Advanced Manufacturing Production Credit.

On July 4, 2025, the One Big Beautiful Bill Act was signed into law in the United States which includes a broad range of tax provisions affecting businesses. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The Company has included the estimated impacts of the bill in the consolidated financial statements for the three-month and six-month periods ended June 30, 2026.

As of December 31, 2025, our federal net operating loss (“NOL”) carryforwards, state net operating loss carryforwards, and federal general business tax credit carryforwards were $8,800, $5,100 and $3,400, respectively. Our domestic net operating loss carryforwards begin to expire in 2031. Our federal general business tax credit carryforwards begin to expire in 2028. As of June 30, 2026, management has concluded it is more likely than not that these domestic NOL and credit carryforwards will be fully utilized.

As of June 30, 2026, for certain past operations in the U.K., we continue to report a valuation allowance for NOL carryforwards of approximately $10,000, nearly all of which can be carried forward indefinitely. Utilization of the net operating losses may be limited due to the change in the past U.K. operation and cannot currently be used to reduce taxable income at our other U.K. subsidiary, Accutronics Ltd. There are no other deferred tax assets related to the past U.K. operations.

As of June 30, 2026, we havenot recognized a valuation allowance against our other foreign deferred tax assets, as realization is considered to be more likely than not.

As of June 30, 2026, the Company maintains its assertion that all foreign earnings will be indefinitely reinvested in those operations, other than earnings generated in the U.K.

There wereno unrecognized tax benefits related to uncertain tax positions at June 30, 2026, and December 31, 2025.

As a result of our operations, we file income tax returns in various jurisdictions including U.S. federal, U.S. state and foreign jurisdictions. We are routinely subject to examination by taxing authorities in these various jurisdictions. Our U.S. tax matters for 2022 thru 2024 remain subject to IRS examination. Our U.S. tax matters for 2005-2007, 2009, and 2011-2015 also remain subject to IRS examination due to the remaining availability of net operating loss carryforwards generated in those years. Our U.S. tax matters for 2015 thru 2024 remain subject to examination by various state and local tax jurisdictions. Our tax matters for the years 2015 through 2024 remain subject to examination by the respective foreign tax jurisdiction authorities.

7.OPERATING LEASES

The Company has operating leases predominantly for operating facilities. As of June 30, 2026, the remaining lease terms on our operating leases range from approximately one (1) year to six (6) years. Lease terms include renewal options reasonably certain of exercise. There is no transfer of title or option to purchase the leased assets upon expiration. There are no residual value guarantees or material restrictive covenants.

The components of lease expense for the current and prior-year comparative periods were as follows:

Three-months endedSix-months ended
June 30, 2026June 30, 2025June 30, 2026June 30, 2025
Operating lease cost$284$291$566$591
Variable lease cost40226146
Total lease cost$324$313$627$637

Supplemental cash flow information related to leases was as follows:

Six-month period ended June 30,
2026 · 2025
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$514$617
Right-of-use assets obtained in exchange for lease liabilities:$-$-

Supplemental consolidated balance sheet information related to leases was as follows:

Balance sheet classification · June 30, 2026 · December 31, 2025
Assets:
Operating lease right-of-use assetOther noncurrent assets$2,883$3,344
Liabilities:
Current operating lease liabilityAccrued expenses and other current liabilities$912$976
Operating lease liability, net of current portionOther noncurrent liabilities1,9942,357
Total operating lease liability$2,906$3,333
Weighted-average remaining lease term (years)3.74.1
Weighted-average discount rate7.2%7.1%

Future minimum lease payments as of June 30, 2026, are as follows:

Maturity of operating lease liabilities
2026$475
2027948
2028937
2029580
2030151
Thereafter189
Total lease payments3,280
Less: Imputed interest(374)
Present value of remaining lease payments$2,906
8.COMMITMENTS AND CONTINGENCIES

Purchase Commitments

As of June 30, 2026, we have made commitments to purchase approximately $301 of production machinery and equipment.

Product Warranties

We estimate future warranty costs to be incurred for product failure rates, material usage and service costs in the development of our warranty obligations. Estimated future costs are based on actual past experience and are generally estimated as a percentage of sales over the warranty period. Changes in our product warranty liability during the first six months of 2026 and 2025 were as follows:

Six-month period ended June 30,
20262025
Accrued warranty obligations – beginning$1,126$887
Accruals for warranties issued164251
Settlements made(51)(173)
Accrued warranty obligations – ending$1,239$965

Contingencies and Legal Matters

We are subject to legal proceedings and claims that arise from time to time in the normal course of business. We believe that the final disposition of any such matters will not have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, recognizing that legal matters are subject to inherent uncertainties, there exists the possibility that ultimate resolution of these matters could have a material adverse impact on the Company’s financial position, results of operations or cash flows. We are not aware of any such situations at this time.

9.REVENUE RECOGNITION

Revenues are generated from the sale of products. Performance obligations are met and revenue is recognized upon transfer of control to the customer, which is generally upon shipment. When contract terms require transfer of control upon delivery at a customer’s location, revenue is recognized on the date of delivery. For products shipped under vendor-managed inventory arrangements, revenue is recognized and billed when the product is consumed by the customer, at which point control has transferred and there are no further obligations by the Company. Revenue is measured as the amount of consideration we expect to receive in exchange for shipped product. Sales, value-added and other taxes billed and collected from customers are excluded from revenue. Customers, including distributors, do not have a general right of return.

Separately priced extended warranty contracts are offered on certain Communications Systems products for a duration of up to eight (8) years. Extended warranties are treated as separate performance obligations and recognized to revenue evenly over the term of the respective contract. Revenue not yet recognized on extended warranty contracts is recorded as deferred revenue on the consolidated balance sheets. For the three-month and six-month periods ended June 30, 2026, revenue recognized on extended warranties was $75 and $149, respectively.

As of June 30, 2026, there was deferred revenue on extended warranty contracts of $706, comprised of $298 expected to be recognized as revenue within one (1) year and classified as accrued expenses and other current liabilities on our consolidated balance sheets, and $408 expected to be recognized as revenue over the remaining duration of the respective contracts and classified as other noncurrent liabilities on our consolidated balance sheets.

As of December 31, 2025, there was deferred revenue on extended warranty contracts of $855, comprised of $298 expected to be recognized as revenue within one (1) year and classified as accrued expenses and other current liabilities on our consolidated balance sheets, and $557 expected to be recognized as revenue over the remaining duration of the respective contracts and classified as other noncurrent liabilities on our consolidated balance sheets.

As of June 30, 2026, and December 31, 2025, the Company had no other unsatisfied performance obligations for contracts with an original expected duration of greater than one year. Pursuant to Topic 606, we have applied the practical expedient with respect to disclosure of the deferral and future expected timing of revenue recognition for transaction price allocated to remaining performance obligations.

10.BUSINESS SEGMENT INFORMATION

Operating segments represent a component of the Company that engages in business activities from which it may recognize revenues and incur expenses whose operating results are regularly reviewed by the public entity’s chief operating decision maker (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance, and for which discrete financial information is available. Upon identification of operating segments, the Company determines which of those operating segments are required to be presented as reportable segments based on the quantitative thresholds.

We structure our operations primarily around the products we sell and report our financial results in the followingtwo reportable segments: Battery & Energy Products and Communications Systems. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical and various other non-rechargeable batteries, in addition to rechargeable batteries, uninterruptable power supplies, charging systems and accessories. The Communications Systems segment includes RF amplifiers, power supplies, cable and connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, integrated communication systems for fixed or vehicle applications and communications and electronics systems design.

Our CODM is Mike Manna, President & Chief Executive Officer. Both of our operating segments are regularly reviewed by the CODM through weekly revenue, gross margin and consolidated financial forecast updates, bi-weekly business and financial reviews to assess business performance, top priorities, utilization of resources and to regularly communicate with segment management, who are part of the CODM’s executive leadership team, and monthly meetings with the executive leadership team. In his role as CODM, Mr. Manna is deeply involved in business operations through daily updates by the segment management and ongoing financial, revenue and operations discussions.

The primary financial measures used by the CODM to monitor and evaluate resource allocation and the performance of the operating segments is segment contribution, as defined by gross profit less direct selling, general and administrative (“SG&A”) and research and development expenses. This metric is used as a consistent benchmark for comparison across reporting periods.

The significant segment expenses regularly reviewed by the CODM and included in segment contribution are cost of products sold and direct R&D and SG&A expenses. There are no other segment items included in segment contribution beyond the significant expenses disclosed.

Corporate general and administrative (“G&A”) expenses, including costs associated with our acquisitions, include corporate functions including board of directors, executive officers, accounting & finance, human resources, legal, information technology and their related functional expenses. These costs are not directly allocable to the operating segments.

The CODM does not review segment assets at a level other than that presented in the Company’s consolidated balance sheets.

Three-month period ended June 30, 2026:

Battery & Energy Products · Communications Systems · Corporate · Total
Revenues$44,189$3,754$-$47,943
Cost of products sold(31,686)(2,391)-(34,077)
Gross profit12,5031,363-13,866
Direct SG&A expenses(4,387)(318)-(4,705)
Research and development(2,303)(922)-(3,225)
Segment contribution5,813123-5,936
Corporate G&A expenses(2,499)(2,499)
Operating income3,437
Other expenses, net(451)(451)
Income tax provision(468)(468)
Non-controlling interest2525
Net income attributable to Ultralife Corporation$2,543
Total assets$169,060$26,969$20,128$216,157
Depreciation and amortization of intangible assets$1,161$49$114$1,324

Three-month period ended June 30, 2025:

Battery & Energy Products · Communications Systems · Corporate · Total
Revenues$45,867$2,694$-$48,561
Cost of products sold(35,032)(1,928)-(36,960)
Gross profit10,835766-11,601
Direct SG&A expenses(4,024)(384)-(4,408)
Research and development(1,494)(824)-(2,318)
Segment contribution5,317(442)-4,875
Corporate G&A expenses(2,619)(2,619)
Operating income2,256
Other expenses, net(1,143)(1,143)
Income tax provision(243)(243)
Non-controlling interest99
Net income attributable to Ultralife Corporation$879
Total assets$170,705$28,330$21,926$220,961
Depreciation and amortization of intangible assets$1,321$58$39$1,418

Six-month period ended June 30, 2026:

Battery & Energy Products · Communications Systems · Corporate · Total
Revenues$88,344$7,044$-$95,388
Cost of products sold(66,483)(4,929)-(71,412)
Gross profit21,8612,115-23,976
Direct SG&A expenses(8,468)(697)-(9,165)
Research and development(4,525)(1,661)-(6,186)
Segment contribution8,868(243)-8,625
Corporate G&A expenses(5,403)(5,403)
Operating income3,222
Other expenses, net(899)(899)
Income tax provision(276)(276)
Non-controlling interest4545
Net income attributable to Ultralife Corporation$2,092
Total assets$169,060$26,969$20,128$216,157
Depreciation and amortization of intangible assets$2,383$106$156$2,645

Six-month period ended June 30, 2025:

Battery & Energy Products · Communications Systems · Corporate · Total
Revenues$92,188$7,119$-$99,307
Cost of products sold(69,913)(5,048)-(74,961)
Gross profit22,2752,071-24,346
Direct SG&A expenses(7,889)(750)-(8,639)
Research and development(3,085)(1,637)-(4,722)
Segment contribution11,301(316)-10,985
Corporate G&A expenses(5,330)(5,330)
Operating income5,655
Other expenses, net(2,096)(2,096)
Income tax provision(810)(810)
Non-controlling interest(5)(5)
Net income attributable to Ultralife Corporation$2,744
Total assets$170,705$28,330$21,926$220,961
Depreciation and amortization of intangible assets$2,586$116$71$2,773

The following tables disaggregate our business segment revenues by major source and geography.

Commercial and Government/Defense Revenue Information:

Three-month period ended June 30, 2026:

Total RevenueCommercialGovernment/ Defense
Battery & Energy Products$44,189$29,860$14,329
Communications Systems3,754-3,754
Total$47,943$29,860$18,083
62%38%

Three-month period ended June 30, 2025:

Total RevenueCommercialGovernment/ Defense
Battery & Energy Products$45,867$31,333$14,534
Communications Systems2,694-2,694
Total$48,561$31,333$17,228
65%35%

Six-month period ended June 30, 2026:

Total RevenueCommercialGovernment/ Defense
Battery & Energy Products$88,344$60,361$27,983
Communications Systems7,044-7,044
Total$95,388$60,361$35,027
63%37%

Six-month period ended June 30, 2025:

Total RevenueCommercialGovernment/ Defense
Battery & Energy Products$92,188$63,620$28,568
Communications Systems7,119-7,119
Total$99,307$63,620$35,687
64%36%

U.S. and Non-U.S. Revenue Information 1:

Three-month period ended June 30, 2026:

Total RevenueUnited StatesNon-United States
Battery & Energy Products$44,189$26,057$18,132
Communications Systems3,7542,5971,157
Total$47,943$28,654$19,289
60%40%

Three-month period ended June 30, 2025:

Total RevenueUnited StatesNon-United States
Battery & Energy Products$45,867$33,300$12,567
Communications Systems2,6942,064630
Total$48,561$35,364$13,197
73%27%

Six-month period ended June 30, 2026:

Total RevenueUnited StatesNon-United States
Battery & Energy Products$88,344$55,001$33,343
Communications Systems7,0444,9042,140
Total$95,388$59,905$35,483
63%37%

Six-month period ended June 30, 2025:

Total RevenueUnited StatesNon-United States
Battery & Energy Products$92,188$68,482$23,706
Communications Systems7,1196,351768
Total$99,307$74,833$24,474
75%25%

1 Sales classified to U.S. include shipments to U.S.-based prime contractors which in some cases may serve non-U.S. projects.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.